Back to search
Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hyperlipidemias, Hypercholesterolemia, Mixed Dyslipidemia trials you may qualify forThis is a multi-center, randomized, double-blind, placebo-controlled phase III clinical study evaluating the efficacy and safety of IBI306 monotherapy in Chines…
The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dy…
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years of age with dyslipidemias that are refr…
This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W \[≤31 days\]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneousl…
The primary objective is to describe in the real-world setting patient characteristics and outcomes of patients with primary hypercholesterolaemia (heterozygous…
The overall objective of the trial is to evaluate the effect of the triple therapy consisting of bempedoic acid (BA), ezetimibe (EZE), and high-intensity atorva…